• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

铂(IV)配合物对 HeLa 细胞球体和单层培养物影响的比较。

Comparison of the Effect of Platinum (IV) Complexes on Spheroids and Monolayer Culture of HeLa Cells.

机构信息

Institute of Problems of Chemical Physics, Russian Academy of Science, Chernogolovka, Moscow, Russia.

Scientific and Educational Center of the Moscow State Regional University in Chernogolovka, Mytishchi, Moscow, Russia.

出版信息

Bull Exp Biol Med. 2020 Feb;168(4):583-588. doi: 10.1007/s10517-020-04757-1. Epub 2020 Mar 9.

DOI:10.1007/s10517-020-04757-1
PMID:32152850
Abstract

We performed a comparative study of the cytotoxicity of cisplatin, JM216 complex, and aminonitroxyl platinum(IV) complexes for HeLa cells grown in monolayer and 3D culture. The growth dynamics of spheroids was studied and optimal conditions for evaluation of cytotoxicity were determined. Spheroids were less sensitive to the test compounds than cells in a monolayer. The resistance index (RI) of spheroids was determined as the ratio of IC for spheroids to IC for monolayer culture. Resistance index was 5.0±1.5 for cisplatin and ranged from 1.8 to 2.3 for platinum(IV) complexes. The observed differences are related to different physicochemical properties of the complexes and different mechanisms of their penetration into cells.

摘要

我们对顺铂、JM216 配合物和氨基亚硝酰基铂(IV)配合物在单层和 3D 培养的 HeLa 细胞中的细胞毒性进行了比较研究。研究了球体的生长动力学,并确定了评估细胞毒性的最佳条件。与单层培养的细胞相比,球体对测试化合物的敏感性较低。球体的耐药指数(RI)定义为球体的 IC 与单层培养的 IC 的比值。顺铂的耐药指数为 5.0±1.5,铂(IV)配合物的耐药指数范围为 1.8 至 2.3。观察到的差异与配合物的不同物理化学性质以及它们进入细胞的不同机制有关。

相似文献

1
Comparison of the Effect of Platinum (IV) Complexes on Spheroids and Monolayer Culture of HeLa Cells.铂(IV)配合物对 HeLa 细胞球体和单层培养物影响的比较。
Bull Exp Biol Med. 2020 Feb;168(4):583-588. doi: 10.1007/s10517-020-04757-1. Epub 2020 Mar 9.
2
Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models.新型铂(IV)化合物与已确立的化疗药物在实体瘤模型中的疗效比较
Biochem Pharmacol. 2004 Jan 1;67(1):17-30. doi: 10.1016/j.bcp.2003.07.016.
3
Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes.通过空间位阻铂(II)配合物克服顺铂耐药性。
Eur J Med Chem. 2016 May 23;114:141-52. doi: 10.1016/j.ejmech.2016.02.060. Epub 2016 Feb 27.
4
New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.新型含金刚烷胺配体的铂(IV)配合物作为一种有前景的抗癌药物:在铂(IV)配合物同系物中对A2780/cisR顺铂耐药细胞系的体外细胞毒性潜力比较
Anticancer Drugs. 2004 Jun;15(5):537-43. doi: 10.1097/01.cad.0000127147.57796.e5.
5
Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.通过“联合作用”模式将顺铂耐药性与氯丁二烯偶联到铂(IV)配合物上以克服顺铂耐药性。
Eur J Med Chem. 2017 Sep 8;137:167-175. doi: 10.1016/j.ejmech.2017.05.056. Epub 2017 May 28.
6
Hyperthermic enhancement of cell killing by five platinum complexes in human malignant melanoma cells grown as monolayer cultures and multicellular spheroids.
Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):491-7. doi: 10.1016/0360-3016(93)90071-3.
7
Bis- and Tetrakis(carboxylato)platinum(IV) complexes with mixed axial ligands - synthesis, characterization, and cytotoxicity.含混合轴向配体的双(羧基)和四(羧基)铂(IV)配合物——合成、表征及细胞毒性
Chem Biodivers. 2015 Apr;12(4):559-74. doi: 10.1002/cbdv.201400291.
8
Synthesis, characterization and biological investigation of platinum(ii) complexes with asparagusic acid derivatives as ligands.以天门冬氨酸衍生物为配体的铂(II)配合物的合成、表征及生物学研究。
Dalton Trans. 2019 Jan 15;48(3):936-944. doi: 10.1039/c8dt02553c.
9
Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.靶向 RAS-RAF 通路显著提高了 Rigosertib 衍生的铂(IV)配合物的抗肿瘤活性,并克服了顺铂耐药性。
Eur J Med Chem. 2020 May 15;194:112269. doi: 10.1016/j.ejmech.2020.112269. Epub 2020 Mar 25.
10
Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors.铂(IV)抗癌配合物与聚(ADP-核糖)聚合酶抑制剂的缀合的合成、细胞毒性和机制研究。
Inorg Chem. 2019 Dec 2;58(23):16279-16291. doi: 10.1021/acs.inorgchem.9b02839. Epub 2019 Nov 18.